XML 15 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Alliances and Related Parties (Details Textual) (USD $)
 3 Months Ended 6 Months Ended 92 Months Ended 6 Months Ended 92 Months Ended 0 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Dec. 31, 2012
Jun. 30, 2012
Dec. 31, 2012
Thera Cour Pharma, Inc [Member]
Dec. 31, 2011
Thera Cour Pharma, Inc [Member]
Dec. 31, 2012
Thera Cour Pharma, Inc [Member]
Feb. 15, 2010
Series Preferred Stock [Member]
Dec. 31, 2012
Series Preferred Stock [Member]
Related Party Transaction, Description of Transaction     charge its costs (direct and indirect) plus no more than 30% of direct costs              
Lab Supplies and Chemicals Fees     $ 25,000              
Other General and Administrative Expense     2,000              
Royalty Payment Percentage Of Net Sales     15.00%              
Preferred Stock, Voting Rights                 nine votes  
Preferred stock, shares issued                 7,000,000 7,000,000
Preferred stock                 7,000 7,000
Development Cost       7,705,488   1,088,484 861,547 861,547    
Security Deposit           649,243   649,243    
Equity Method Investment, Ownership Percentage 21.00%   21.00% 21.00%   70.00%   70.00%    
Common stock, shares, outstanding 160,911,462   160,911,462 160,911,462 155,612,293 33,360,000   33,360,000    
Lab Fees $ 561,618 $ 0   $ 2,421,755            
Convertible Preferred Stock, Terms of Conversion                 The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Company's intellectual property, into shares of the Company's common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.